I-Mab IMAB

NAS: IMAB | ISIN: US44975P1030   17:10
1,755 USD (-0,85%)
(-0,85%)   17:10

30 april 2024 · I-MAB Filed 2023 Annual Report on Form 20-F · Persbericht

5 april 2024 · I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

2 april 2024 · I-Mab Announces Closing of the Divestiture of Business Operations in China · Persbericht

14 maart 2024 · I-Mab Reports Full Year 2023 Financial Results and Business Update · Persbericht

7 februari 2024 · I-Mab Signs Agreement to Divest its Assets and Business Operations in China · Persbericht

6 november 2023 · I-Mab Announces Participation at Jefferies and Piper Conferences in November · Persbericht

2 november 2023 · Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) · Persbericht

1 november 2023 · I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 · Persbericht

16 oktober 2023 · I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 · Persbericht

10 oktober 2023 · I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 · Persbericht

4 oktober 2023 · Thinking about buying stock in ALX Oncology Holdings, RedHill Biopharma, Freeline Therapeutics Holdings, Terawulf, or I-Mab? · Persbericht

5 september 2023 · I-Mab Announces Upcoming Participation at September Conferences · Persbericht

17 augustus 2023 · I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates · Persbericht

8 augustus 2023 · I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 · Persbericht

5 juli 2023 · I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC · Persbericht

22 juni 2023 · I-Mab Announces the Appointment of Raj Kannan as CEO · Persbericht

25 mei 2023 · I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 · Persbericht

1 mei 2023 · I-MAB Filed 2022 Annual Report on Form 20-F · Persbericht

26 april 2023 · I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 · Persbericht

25 april 2023 · I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon · Persbericht

Mijn selecties